{"id":"3bc7cc8f-16eb-4bcc-a12e-968036718398","arxiv_id":"2411.10511","paper_version":4,"verdict":"CONDITIONAL","confidence":"HIGH","novelty_score":3.0,"correctness_risk":"medium","formal_verification":"none","parameter_count":0,"one_line_summary":"A review argues that quantum computing, particularly quantum machine learning, could enhance biomarker discovery for small, high-dimensional, and noisy healthcare datasets.","lead":"This perspective maps quantum machine learning algorithms to biomarker discovery problems across EHRs, omics, and medical images, organizing opportunities by data type. It argues that small, high-dimensional, and noisy datasets common in biomarker research could be a natural fit for quantum algorithms, though major hardware and data-loading hurdles remain.","discovery_kind":"review","skeptic_critique":{"model":"deepseek-v4-flash","headline":"Few-sample QML generalization advantage is cited as established but the source supports only absolute bounds, not superiority over classical models; the roadmap's main enabler is therefore unsupported.","rationale":"The reader's weakest_assumption identifies the few-sample QML generalization advantage, and my reading agrees that this is the load-bearing premise. The paper's central assertion in the abstract—that quantum computing offers 'advanced information processing and means to detect complex correlations'—is operationalized largely through quantum machine learning applied to small-sample, high-dimensional biomarker data. If quantum models do not genuinely generalize better than classical models from few samples, then the specific opportunities mapped in Section 3 (QML for EHRs, omics, and images) lose their claimed edge, even though the paper could still stand as a general taxonomy of algorithms. My concern is not that the paper lacks a proof—this is a perspective—but that it cites a theoretical result as if it established a comparative advantage that the result does not actually claim. This is an internal accuracy issue, not merely a disagreement with the broader consensus that quantum advantage is unproven. The paper itself acknowledges that 'the predictive advantage of QML models for practically relevant problems remains an open question' (Section 2.1), yet the later sections proceed to assert such advantages (e.g., 'demonstrable impact' in omics, Section 3.1.2; QTDA for early cancer differentiation, Section 3.2.2). That inconsistency supports the reader's CONDITIONAL verdict: the roadmap is useful but its central motivation is an overstatement that should be explicitly flagged as an open hypothesis. A concrete empirical benchmark on realistic biomarker data would settle the concern directly, because the claim is about predictive performance, not just theoretical bounds. My recommendation is UNCHANGED because the reader's CONDITIONAL verdict already captures the appropriate level of caution; my stress test reinforces it without adding a new failure mode that would require rejection. The paper can be accepted as a perspective if the overclaim is toned down and the few-sample advantage is presented as a research question rather than an expected outcome.","tokens_in":25526,"tokens_out":4644,"duration_ms":45753,"concrete_test":"Run a nested cross-validation benchmark on a published small-sample biomarker dataset (e.g., a gene-expression cohort with n≈50–100 samples, p>10,000 features): compare a classical RBF-kernel SVM and elastic-net logistic regression against a quantum kernel (ZZFeatureMap or projected kernel) and a variational quantum classifier on the same preprocessed features, measuring mean AUC and 95% CI. If the quantum models do not significantly exceed the classical baselines, the 'better generalization' premise in Section 2.1 is falsified for this data regime; if they do, the claim gains direct support.","verdict_should_be":"UNCHANGED","load_bearing_attack":"The paper's central enabler is the claim in Section 2.1 that 'quantum models are expected to show better generalization than classical models, leveraging fewer data points [29].' This is presented as the basis for the small-sample opportunities in Sections 3.1 and 3.3.1. However, reference [29] (Caro et al., Nat. Commun. 2022) proves generalization bounds for quantum models trained on few data, showing that error can be small if the model class has bounded complexity; it does not demonstrate that quantum models outperform classical models on the same data. Absolute generalization guarantees do not constitute relative advantage, and classical kernel methods or regularized linear models can also generalize well in high-dimensional low-sample settings. The paper later concedes that data loading can erase quantum advantages (Section 3.1), then argues small data avoids this problem, but that argument only holds if the few-sample advantage is real. No empirical comparison on realistic biomarker datasets is provided; the cited QSVM-on-EHR studies (refs [166,167]) show competitiveness, not superiority. If the comparative advantage is absent, the roadmap's main motivation—that small-sample, high-dimensional biomarker data is where quantum computing helps—lacks support, and the paper reduces to a taxonomy of algorithms without an evidence-based central claim.","agreement_with_reader":"agree"},"referee_report":{"model":"deepseek-v4-flash","summary":"This perspective paper maps gate-based quantum computing algorithms, particularly quantum machine learning, to problems in biomarker discovery. The authors organize the analysis by data type (multi-dimensional, time series, erroneous) and cover three healthcare data modalities (EHRs, omics, and medical images). For each combination, they describe classical limitations, proposed quantum algorithms, and open challenges such as data loading, barren plateaus, and the need for benchmarks. The paper is explicitly framed as a perspective, not as a new technical result, and it repeatedly acknowledges that most computational steps remain classical and that quantum advantage is not yet established for most applications.","tokens_in":25729,"tokens_out":3623,"duration_ms":33541,"significance":"The paper provides a useful, clearly structured taxonomy that connects quantum algorithm families to concrete biomarker discovery problems, which can help orient researchers in both fields. Its main virtue is honesty: it flags data loading as a potential showstopper, discusses barren plateaus and classical simulability, and emphasizes the need for use-case-specific algorithm design. The roadmap is plausible as a research agenda. However, the central motivation for the small-sample opportunity rests on a claim about few-sample generalization that is not supported by the cited literature, and at least one specific application claim (QTDA for early cancer differentiation) is made without evidence. If these issues are corrected, the perspective would be a solid contribution; as written, the central enabling premise is overstated.","major_comments":[{"comment":"The sentence \"quantum models are expected to show better generalization than classical models, leveraging fewer data points [29]\" is not supported by the cited reference. Caro et al. (Nat. Commun. 2022) prove generalization bounds for quantum models trained on few data, but these are absolute bounds that do not establish superiority over classical models; classical regularized models or kernel methods can also generalize well in high-dimensional low-sample regimes. This claim is load-bearing because it is invoked to motivate the small-sample opportunities in Sections 3.1.1 (EHR small-cohort studies), 3.1.2 (omics), and 3.3.1 (small datasets generally). The cited empirical studies [166,167] show QSVM competitiveness, not superiority. Please rephrase the claim to state that quantum models can have favorable generalization properties in certain settings, with no proven comparative advantage, and add a reference that explicitly discusses the relative quantum-vs-classical question (e.g., the benchmarking study [25]).","section":"Section 2.1"},{"comment":"The statement that QTDA \"could be used to differentiate with high accuracy between healthy individuals and cancer patients in early stages of diseases\" is unsupported: no citation is given, and QTDA per se is a topological data analysis tool, not a classifier. In a perspective, speculative statements are acceptable if clearly labeled, but this sentence presents a substantial empirical claim as a foreseeable outcome. Either remove the clause or explicitly frame it as a speculative hypothesis requiring empirical validation.","section":"Section 3.2.2"}],"minor_comments":[{"comment":"The citation \"[12, 154–157] [157]\" contains a duplicate reference; it should be \"[12, 154–157]\".","section":"Section 3.3"},{"comment":"References [93] and [170] are the same paper (Nalecz-Charkiewicz et al., \"Quantum computing in bioinformatics: a systematic review mapping\"). They should be consolidated into a single reference.","section":"References"},{"comment":"Typographical errors: \"GW AS\" should be \"GWAS\", and \"underling modality\" should be \"underlying modality\". In Figure 1, \"strati/f_ication\" appears to be a LaTeX rendering artifact and should be corrected.","section":"Section 3.1"},{"comment":"The phrase \"in analogy to central (CPUs) and graphics processing units (GPUs)\" should be \"central processing units (CPUs) and graphics processing units (GPUs)\".","section":"Section 2"},{"comment":"The figure caption uses many abbreviations (QML, QGAN, QVAE, QTDA, QGNNs, etc.) without defining them. Please expand the caption or refer the reader to the table and text where these are defined.","section":"Figure 1"},{"comment":"The phrase \"QRC techniques are relevant techniques\" is redundant; consider rewording to \"QRC is a relevant technique\".","section":"Section 3.2.3"}],"recommendation":"major_revision","confidential_remarks":"The paper is a perspective, so the bar for proof is appropriately lower than for a research article. However, the unsupported comparative generalization claim in Section 2.1 is central to the paper's small-data narrative and should be corrected rather than merely softened. The duplication of references and several typos suggest the manuscript would benefit from a careful proofreading pass. The paper's scope fits q-bio.OT well, and with the requested revisions it could be a useful contribution to the community."},"author_rebuttal":null,"desk_editor":{"model":"deepseek-v4-flash","letter":"Here's the quick take: if someone wants a single map of which quantum algorithms might matter for which biomarker data problems, this is genuinely useful. The data-type-by-modality framing (multi-dimensional/time-series/erroneous x EHR/omics/images) is a good organizing device, and the authors cover a lot of ground without pretending the field is further along than it is. They repeatedly flag data loading, barren plateaus, and hardware constraints, and the conclusion is appropriately cautious.\n\nThe main soft spot, and it's a load-bearing one, is their use of Caro et al. [29] to support the claim that 'quantum models are expected to show better generalization than classical models, leveraging fewer data points.' Caro et al. proves absolute generalization bounds for few-shot QML; it does not show quantum models beat classical models on the same data. The paper's whole small-sample motivation in Section 3.1 and 3.3.1 leans on that comparative advantage. Since the authors themselves concede data loading can erase quantum advantages, the argument only survives if the few-sample advantage is real—and that's exactly what's not established. That's not a fatal flaw for a perspective, but it should be toned down from 'expected' to 'hypothesized.'\n\nThere are a couple of smaller overclaims: the QTDA sentence about differentiating cancer patients at early stages (Section 3.2.2) is speculative without support, and 'demonstrable impact' in omics (Section 3.1.2) is stronger than the cited works show. Also, the self-citations are fine—they're prior independent works—but the reader should know the authors are citing their own group's papers in a few places.\n\nWho is this for? Anyone starting in this intersection, or a referee wanting a balanced overview. It's not a technical result, so the value is organizational. I don't think my own work will cite it, but I'd send it to a reading group as a shared reference.\n\nVerdict: with light revision (fix the [29] overreach, moderate the QTDA and omics claims), it's a solid perspective. A serious editor should send it to peer review rather than desk reject; the framework is useful and the literature coverage is broad. I'd sign off on it after those changes.","headline":"A well-organized QC-for-biomarker perspective whose central few-sample QML advantage claim overreaches its cited source; worth reviewing after modest revisions.","tokens_in":26301,"tokens_out":4173,"would_cite":false,"duration_ms":31257,"reading_group":"yes","serious_thinker":"yes","would_accept_peer_review":true},"rs_alignment":null,"lean_confirmation":null,"pith_extraction":{"msc":[],"pacs":[],"model":"deepseek-v4-flash","headline":"This perspective paper argues that quantum computing, especially quantum machine learning, is most promising for biomarker discovery in small, high-dimensional, longitudinal, or noisy healthcare datasets, and maps algorithms to those data…","keywords":["quantum machine learning","biomarker discovery","electronic health records","omics data","medical imaging","time series data","small-sample learning","data loading"],"falsifier":"Run a head-to-head benchmark on a fixed realistic biomarker cohort (for example, a thousand-patient EHR or omics dataset) in which quantum and classical models receive identical preprocessing, encoding, and compute budget, and compare generalization across repeated train/test splits; if the quantum model's generalization gap is not smaller than the best classical baseline, the paper's few-sample advantage premise is not supported.","tokens_in":25326,"feed_emoji":"🧬","tokens_out":7749,"duration_ms":64856,"temperature":0.7,"pith_summary":"This perspective paper maps quantum algorithms, especially quantum machine learning, to biomarker-discovery problems they might plausibly help with. It argues the best fit is not big-data medicine but the difficult corners: datasets with many features and few samples, time series with missing or irregular measurements, and data whose labels are unreliable. The paper organizes opportunities by data type — multi-dimensional, time series, and erroneous — and examines EHRs, omics, and medical images under each. It does not claim a proven quantum advantage; it identifies where advantage could arise and what must be solved first.","feed_headline":"Quantum machine learning could find biomarkers where data is scarce","feed_subtitle":"The payoff could be in few-sample cohorts, longitudinal records, and noisy labels.","key_machinery":"The organizing device is a three-way classification of biomarker data by structure — multi-dimensional, time series, and erroneous — crossed with three healthcare modalities (EHRs, omics, medical images). Within that grid, the load-bearing algorithmic idea is the hybrid variational quantum algorithm: a parametrized quantum circuit whose parameters are optimized by a classical computer, together with an embedding that maps classical data into Hilbert space. The paper treats generalization from few training samples as the specific mechanism by which quantum machine learning could beat classical methods, and treats data loading as the mechanism that could erase that advantage.","core_discovery":"The paper's central claim is that quantum computing can enhance biomarker discovery for healthcare data that is multi-dimensional, time-series, or erroneous, and that the most credible near-term opportunities lie in small-sample, high-dimensional settings where quantum models are expected to generalize from few data points. It maps specific quantum algorithms to specific problems: dimensionality reduction (QPCA and variants), classification (QNNs and quantum kernels), regression, clustering, generative models, time-series forecasting (quantum reservoir computing), and error handling. It argues that data loading into quantum computers is the central bottleneck and can erase claimed advantages, and that near-term practical gains are therefore more likely in small data than in big data.","pith_inferences":["The paper leaves implicit that its data-type grid could serve as an algorithm-selection checklist: match quantum methods to settings where classical models overfit, extrapolate poorly, or cannot encode long-range correlations.","A testable extension of the roadmap is to apply quantum reservoir computing not only to EHR time series but to multi-omics longitudinal data such as cell-free DNA fragmentomics, where small-sample extrapolation is the stated failure mode.","The roadmap implies that benchmarks for quantum biomarker discovery should include noisy-label and missing-data settings rather than clean curated data, because that is where the paper locates the strongest opportunity.","If few-sample generalization holds, the highest-value demonstration would be a clinical dataset with fewer than a few hundred samples, comparing quantum kernels and quantum neural networks against well-tuned classical baselines with identical preprocessing."],"forward_implications":["If quantum models genuinely generalize from fewer samples, small-cohort studies — rare disease cohorts and clinical trial subgroups — are the most plausible earliest adopters of quantum-enhanced biomarker discovery.","For multi-dimensional omics and imaging data, quantum dimensionality reduction and clustering could become practical only after data-loading bottlenecks and fault-tolerance issues are resolved.","Quantum reservoir computing could address longitudinal EHR and wearable data, but only if the encoding of that data does not erase the quantum advantage.","Quantum generative models could support synthetic data or imputation for missing and erroneous biomarker data, improving downstream classical analysis.","Near-term practical wins are more likely on small data than on big data, which runs against the usual big-data framing of quantum computing in healthcare."],"supporting_citations":[{"why":"It supplies the few-sample generalization result that the paper leans on for small-cohort biomarker discovery.","marker":"[29]"},{"why":"It is the benchmarking study used to argue that problem-agnostic quantum machine learning models will not beat classical ones, motivating tailored designs.","marker":"[25]"},{"why":"It establishes the data-dependent predictive advantage of quantum kernel models, grounding the classification claims.","marker":"[28]"},{"why":"It introduces supervised learning with quantum-enhanced feature spaces, the basis for the quantum kernel approach.","marker":"[19]"},{"why":"It provides the quantum convolutional neural network as evidence for data- and model-size-efficient quantum learning.","marker":"[37]"},{"why":"It shows that QPCA's speedup depends on state-preparation assumptions, supporting the paper's caveat that data loading can erase quantum advantages.","marker":"[72]"},{"why":"It is cited as the hardware direction (quantum random access memory) for solving the data-loading bottleneck.","marker":"[73]"},{"why":"It is cited for the claim that quantum generative models can show practical advantage on small datasets.","marker":"[168]"}],"fun_headline_variants":["Quantum computing's biomarker edge is in small data","Small data, quantum boost: finding biomarkers sooner","Quantum ML targets biomarkers from scarce health data","Biomarker discovery via quantum machine learning"],"cache_read_input_tokens":3200,"weakest_assumption_plain":"The argument stands on the claim that quantum machine-learning models trained on very few patient samples can generalize better than classical models on realistic biomarker data, and that this advantage survives data encoding and hardware noise.","fun_headline_variants_meta":{"raw":{"variants":["Quantum computing's biomarker edge is in small data","Small data, quantum boost: finding biomarkers sooner","Quantum ML targets biomarkers from scarce health data","Biomarker discovery via quantum machine learning"]},"model":"deepseek-v4-flash","effort":"low","cost_usd":0.000147,"raw_usage":{"total_tokens":1111,"prompt_tokens":794,"completion_tokens":317,"prompt_tokens_details":{"cached_tokens":384},"prompt_cache_hit_tokens":384,"prompt_cache_miss_tokens":410,"completion_tokens_details":{"reasoning_tokens":260}},"tokens_in":410,"tokens_out":317,"duration_ms":3640,"temperature":1.0,"reasoning_tokens":260,"cache_read_input_tokens":384,"cache_creation_input_tokens":0},"cache_creation_input_tokens":0},"created_at":"2026-08-12T19:41:53.615596+00:00","model_set":{"reader":"deepseek-v4-flash"},"falsifier":"Run a head-to-head benchmark on a fixed realistic biomarker cohort (for example, a thousand-patient EHR or omics dataset) in which quantum and classical models receive identical preprocessing, encoding, and compute budget, and compare generalization across repeated train/test splits; if the quantum model's generalization gap is not smaller than the best classical baseline, the paper's few-sample advantage premise is not supported.","supporting_citations":[{"cited_title":"Communications Physics 7(1), 68 (2024)","cited_arxiv_id":null,"evidence_quote":"It is cited for the claim that quantum generative models can show practical advantage on small datasets."}],"review_version":1}